Abstract
New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy. Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events. Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3-4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or anorexia. The peripheral sensory neuropathy rate w...Continue Reading
References
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Jul 14, 2010·Maternal & Child Nutrition·Setsuko TsutieTetsuya Inatome
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Aug 15, 2014·Cancer Science·Takuji OkusakaNarikazu Boku
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 5, 2016·Cancer Chemotherapy and Pharmacology·Hideki UenoJunji Furuse
Dec 29, 2016·World Journal of Gastroenterology : WJG·Marwan GhosnJoseph Kattan
Jan 8, 2017·Pathology Oncology Research : POR·G LakatosG Bodoky
May 13, 2017·The Lancet Oncology·Angela AlistarBoris Pasche
Oct 14, 2017·Journal of Thrombosis and Haemostasis : JTH·K DateA Maraveyas
Oct 21, 2017·Clinical Journal of Gastroenterology·Minami HashimotoHiromasa Ohira
Citations
Jun 1, 2019·Expert Review of Anticancer Therapy·Veethika Pandey, Peter Storz
Jun 4, 2019·The New England Journal of Medicine·Talia GolanHedy L Kindler
Nov 7, 2019·Cancer Chemotherapy and Pharmacology·Hiroki IrieHiromasa Ohira
Jul 1, 2020·American Journal of Clinical Oncology·Jong-Chan LeeJin-Hyeok Hwang
Jul 17, 2020·Cancer Reports·Kiyotsugu IedeShusei Tominaga
Apr 10, 2019·Cancers·Sara PuscedduFausto Petrelli
Oct 11, 2019·Therapeutic Advances in Gastroenterology·Nicolas WillietJulien Taieb
Nov 15, 2019·Cancer Medicine·Kelvin K W ChanErin D Kennedy
Sep 22, 2020·World Journal of Clinical Cases·Sung Yong HanHyung-Il Seo
Sep 6, 2020·American Journal of Clinical Oncology·Jong-Chan LeeJin-Hyeok Hwang
Jun 18, 2019·Therapeutic Advances in Medical Oncology·Elena Gabriela ChioreanSalah-Eddin Al-Batran
Jan 24, 2021·International Journal of Clinical Oncology·Taiga OtsukaNorio Ureshino
Oct 24, 2020·Investigational New Drugs·Kei SaitoKazuhiko Koike
Mar 14, 2021·Seminars in Oncology·Celine Yeh, Susan E Bates
Jun 23, 2021·World Journal of Surgical Oncology·Beilei ZhangYunbao Xu
Jul 3, 2021·Cancers·Nicolas WillietJean Marc Phelip
Jul 25, 2021·BMC Cancer·Jiayuan ChenZhenyu Lin
Jul 23, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Héctor G van den BoornHanneke W M van Laarhoven
Oct 12, 2021·Oncology Letters·Leonel PekarekMiguel A Ortega
Oct 13, 2021·Scientific Reports·Yoon Suk LeeJin-Hyeok Hwang